Investing in Breakthrough Medicines
East Rocky Asset Management
East Rocky Asset Management is a specialist Health Sciences investment manager founded by Dr Tom Tang in 2022. The firm applies deep scientific and clinical research to identify mispriced companies developing breakthrough medicines, with particular expertise in oncology and neurodegenerative diseases and opportunistic investment across other therapeutic areas.
Investment Philosophy
Scientific Understanding
Deep understanding of disease biology, therapeutic mechanisms and clinical evidence can reveal opportunities the market has mispriced.
The Underlying Therapy
We assess each therapy’s scientific potential alongside its addressable market, commercial opportunity and valuation.
Independent Thinking
Independent research helps us identify non-consensus opportunities where our assessment differs from market expectations.
East Rocky Health Sciences Strategy
A Long short health sciences strategy investing across 50–70 long and short positions, using deep scientific and clinical research to identify mispriced companies developing breakthrough medicines.
